Record Sales Result of $2.4m in Q1
Released
Released
Announcement PDF
The Calmer Co International Limited
96 Victoria Street West End Queensland 4101
ACN: 169 441 874
3rd
October 2025 ASX RELEASE
Record Sales Result of $2.4m in Q1
Brisbane, Australia – The Calmer Co. International Limited (ASX: CCO), a leading consumer
packaged goods company specialising in kava and other natural products that promote
relaxation, sleep support, and healthier alternatives to alcohol, is pleased to announce that
it has achieved the highest quarterly revenue in its history.
For the first quarter of FY26, the Company delivered record sales of $2.4 million,
representing a 26% increase on the previous quarter (Q4 FY25: $1.9 million).
Highlights
• Record quarterly revenue of $2.4 million, the strongest result in Company
history, and a 26% improvement over the previous quarter ($1.9m, Q4FY25).
• Australian sales of $1.4 million, up 30% vs Q4 FY25, led by retail distribution
through Coles and Woolworths.
• USA sales of $936k, up 20% vs Q4 FY25, supported by Amazon launches of new
product formats.
• B2B sales of $290k, up 20% vs Q4 FY25, underpinned by growing orders from
partners and IMCD’s Network Nutrition.
• Secured commitments for $700,000 as the first tranche of a proposed two-
tranche, $1,400,000 secured convertible note issuance to support wholesale
inventory build and growth initiatives, ensuring the Company is well resourced to
execute its strategy and remain on track to achieve breakeven.
Founder and CEO, Zane Yoshida, commented:
“Our lower cost and more diversified sales and marketing strategies are now delivering
growth across all channels. New product launches on Amazon USA are showing pleasing
signs of the potential of this market. Australian retail sales remain extremely strong and
more profitable than the eCommerce-led strategy originally used to penetrate the market.
Meanwhile, eCommerce in both Australia and the USA, through the Acuity platform,
continues to grow at a much lower investment level.
Our B2B business, which now includes market-leading extracts at higher kavalactone
concentrations, has also shown exceptional growth, underpinned by increasing orders
from strategic partners and IMCD’s Network Nutrition. The renewed engagement from
Applied Food Sciences and their participation in our recent funding further validates
our strategy and highlights the global potential of kava.”
This announcement has been approved by the Board of Directors.
2
ends
For further information
Investor & Media Relations
Matthew Reede
Dominion Communications
matt@dominion.partners
+61 414 483 054
About The Calmer Co.
The Calmer Co. International Limited (ASX:CCO) is a fast growing beverage business
leveraging a global opportunity in kava and other natural products that replace alcohol and
support relaxation and sleep.
Our products are delivered to consumers globally through e-commerce channels and blue-
chip retail distribution partners, supported by a reliable farm to shelf supply chain.
The product range includes drinking powders, natural and flavoured kava shots,
concentrates and capsules, sold under the brands Fiji Kava, Taki Mai and Danodan
Hempworks in markets including USA, Australia, New Zealand, China and the Pacific
Islands.
Forward looking statements
This ASX release includes certain forward-looking statements that are based on
information and assumptions known to date and are subject to various risks and
uncertainties. Actual results, performance or achievements could be significantly different
from those expressed in, or implied by, these forward-looking statements. Such forward-
looking statements are not guarantees of future performance and involve known and
unknown risks, uncertainties and other factors, many of which are beyond the control of
the Company. These factors may cause actual results to differ materially from those
expressed in the statements contained in this announcement.
https://thecalmerco.com/link/eolMpr
Share your feedback
Discover